Paper40960554
The benefits of combining an immunomodulator with a chemotherapy agent in chondrosarcoma-a proof of concept with mifamurtide.
Quoniou R and 5 others. Med Oncol, 2025. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. The benefits of combining an immunomodulator with a chemotherapy agent in chondrosarcoma-a proof of concept with mifamurtide. Papers, record 40960554. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40960554
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The benefits of combining an immunomodulator with a chemotherapy agent in chondrosarcoma-a proof of concept with mifamurtide.
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Chondrosarcoma | Major topic |
| Bone Neoplasms | Major topic |
| Acetylmuramyl-Alanyl-Isoglutamine | Major topic |
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Humans | |
| Animals | |
| Mice | |
| Tumor-Associated Macrophages | |
| Cell Line, Tumor | |
| Proof of Concept Study | |
| Doxorubicin | |
| Xenograft Model Antitumor Assays | |
| Coculture Techniques | |
| Phosphatidylethanolamines |
Source PubMed
References50
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 37958467 | The Role of Macrophages in Sarcoma Tumor Microenvironment and Treatment. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37958467 | PubMed |
| 2 | 37174021 | Molecular In-Depth Characterization of Chondrosarcoma for Current and Future Targeted Therapies. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37174021 | PubMed |
| 3 | 23483678 | Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors. | Oncoimmunology | 2013 | https://conductscience.org/library/papers/23483678 | PubMed |
| 4 | 36868333 | Lactate induces tumor-associated macrophage polarization independent of mitochondrial pyruvate carrier-mediated metabolism. | Int J Biol Macromol | 2023 | https://conductscience.org/library/papers/36868333 | PubMed |
| 5 | 33912442 | High TIL, HLA, and Immune Checkpoint Expression in Conventional High-Grade and Dedifferentiated Chondrosarcoma and Poor Clinical Course of the Disease. | Front Oncol | 2021 | https://conductscience.org/library/papers/33912442 | PubMed |
| 6 | 26912558 | Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies. | Ann Oncol | 2016 | https://conductscience.org/library/papers/26912558 | PubMed |
| 7 | 12115575 | Supra-additive effect with concurrent paclitaxel and cisplatin in vulvar squamous cell carcinoma in vitro. | Int J Cancer | 2002 | https://conductscience.org/library/papers/12115575 | PubMed |
| 8 | 23348699 | Tumor-associated macrophages as potential diagnostic and prognostic biomarkers in breast cancer. | Cancer Lett | 2013 | https://conductscience.org/library/papers/23348699 | PubMed |
| 9 | 27312065 | Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype. | Mod Pathol | 2016 | https://conductscience.org/library/papers/27312065 | PubMed |
| 10 | 31412220 | CD40 Agonist Antibodies in Cancer Immunotherapy. | Annu Rev Med | 2020 | https://conductscience.org/library/papers/31412220 | PubMed |
| 11 | 10884587 | Synergistic anti-tumor activity of a novel immunomodulator, BCH-1393, in combination with cyclophosphamide. | Int J Immunopharmacol | 2000 | https://conductscience.org/library/papers/10884587 | PubMed |
| 12 | 26966341 | Tumor-Associated Macrophages and Neutrophils in Tumor Microenvironment. | Mediators Inflamm | 2016 | https://conductscience.org/library/papers/26966341 | PubMed |
| 13 | 28380460 | CD47 promotes ovarian cancer progression by inhibiting macrophage phagocytosis. | Oncotarget | 2017 | https://conductscience.org/library/papers/28380460 | PubMed |
| 14 | 31629410 | Tumor-associated macrophages: an accomplice in solid tumor progression. | J Biomed Sci | 2019 | https://conductscience.org/library/papers/31629410 | PubMed |
| 15 | 29632713 | CD47 is a direct target of SNAI1 and ZEB1 and its blockade activates the phagocytosis of breast cancer cells undergoing EMT. | Oncoimmunology | 2018 | https://conductscience.org/library/papers/29632713 | PubMed |
| 16 | 34830082 | 3D Cell Culture Systems: Tumor Application, Advantages, and Disadvantages. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34830082 | PubMed |
| 17 | 27994517 | Cyclooxygenase-2 in tumor-associated macrophages promotes metastatic potential of breast cancer cells through Akt pathway. | Int J Biol Sci | 2016 | https://conductscience.org/library/papers/27994517 | PubMed |
| 18 | 28704566 | Development and characterization of a human three-dimensional chondrosarcoma culture for in vitro drug testing. | PLoS One | 2017 | https://conductscience.org/library/papers/28704566 | PubMed |
| 19 | 22314082 | Contribution of CXCL12 secretion to invasion of breast cancer cells. | Breast Cancer Res | 2012 | https://conductscience.org/library/papers/22314082 | PubMed |
| 20 | 25082815 | CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. | Cancer Res | 2014 | https://conductscience.org/library/papers/25082815 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40960554
GET https://conductscience.org/api/papers/v1/40960554/references?page=2